Who Exports Meropenem from India — 401 Suppliers Behind a $222.9M Market
India's meropenem export market is supplied by 401 active exporters who collectively shipped $222.9M across 3,658 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 39.9% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and VENUS REMEDIES LIMITED. The top 5 suppliers together control 82.7% of total export value, reflecting a concentrated market structure.
Top Meropenem Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading meropenem exporter from India, holding a 39.9% share of the $222.9M market across 3,658 shipments from 401 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, VENUS REMEDIES LIMITED, GUFIC BIOSCIENCES LIMITED, BROOKS STERISCIENCE LIMITED — collectively control 82.7% of total export value, indicating a highly concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (39.9%), EUGIA PHARMA SPECIALITIES LIMITED (19.9%), VENUS REMEDIES LIMITED (19.2%), GUFIC BIOSCIENCES LIMITED (2.4%), BROOKS STERISCIENCE LIMITED (1.2%).
Top Meropenem Exporters from India
Ranked by export value · 401 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED MEROPENEM SUN INJ 1G 10X1V 30ML IT PACKMEROPENEM SUN INJ 1G 10X1V 30ML SE/FI PAMEROPENEM RANBAXY 1GM PACK:5 VIALS BATCH | $89.0M | 16 | 39.9% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED MEROPENEM FOR INJECTION 1 G/VIAL (MEROPEMEROPENEM FOR INJECTION USP 1G/VIAL, 30ML VIALMEROPENEM 1.0 GM POWDER FOR SOLUTION FOR | $44.3M | 18 | 19.9% |
| 3 | VENUS REMEDIES LIMITED MEROPENEM RANBAXY 1GM PACK:5 VIALS BATCHMEROPENEM 1.0 GM POWDER FOR SOLUTION FORMEROPENEM RANBAXY 500 MG PACK:5 VIALS BA | $42.9M | 41 | 19.2% |
| 4 | GUFIC BIOSCIENCES LIMITED MEROFIC 1G INJMEROFIC 1G MEROPENEM INJECTION 1G (BATCHMEROFIC 1G | $5.4M | 4 | 2.4% |
| 5 | BROOKS STERISCIENCE LIMITED MEROPENEM FOR INJECTION 1 G/VIAL (MEROPEMEROPENEM FOR INJECTION USP 1G/VIAL, 30ML VIALMEROPENEM FOR INJECTION 1 G/VIAL,(MEROPE | $2.8M | 9 | 1.2% |
| 6 | VENUS REMEDIES LTD MEROPENEM RANBAXY 1GM PACK:5 VIALS BATCHMEROPENEM 1.0 GM POWDER FOR SOLUTION FORMEROPENEM RANBAXY 500 MG PACK:5 VIALS BA | $2.4M | 10 | 1.1% |
| 7 | VHB MEDI SCIENCES LIMITED | $2.4M | 4 | 1.1% |
| 8 | MAAN PHARMACEUTICALS LIMITED MEROFIC 1G INJMEROFIC 1G MEROPENEM INJECTION 1G (BATCHMEROFIC 1G | $2.3M | 1 | 1.0% |
| 9 | GLAND PHARMA LIMITED MEROPENEM FOR INJECTION 1 G/VIAL (MEROPEMEROPENEM FOR INJECTION USP 1G/VIAL, 30ML VIALMEROPENEM 1.0 GM POWDER FOR SOLUTION FOR | $2.1M | 2 | 0.9% |
| 10 | SWISS PARENTERALS LIMITED MEROFIC 1G INJMEROFIC 1G MEROPENEM INJECTION 1G (BATCHMEROFIC 1G | $2.0M | 14 | 0.9% |
| 11 | M. J. BIOPHARM PRIVATE LIMITED | $1.4M | 9 | 0.6% |
| 12 | SUN PHARMACEUTICAL INDUSTRIES LTD MEROPENEM SUN INJ 1G 10X1V 30ML IT PACKMEROPENEM SUN INJ 1G 10X1V 30ML SE/FI PAMEROPENEM RANBAXY 1GM PACK:5 VIALS BATCH | $967.6K | 6 | 0.4% |
| 13 | GLAND PHARMA LTD MEROPENEM FOR INJECTION 1 G/VIAL (MEROPEMEROPENEM FOR INJECTION USP 1G/VIAL, 30ML VIALMEROPENEM 1.0 GM POWDER FOR SOLUTION FOR | $936.6K | 1 | 0.4% |
| 14 | M J BIOPHARM PRIVATE LIMITED MEROPENEM SUN INJ 1G 10X1V 30ML IT PACKMEROPENEM SUN INJ 1G 10X1V 30ML SE/FI PAMEROPENEM RANBAXY 1GM PACK:5 VIALS BATCH | $745.1K | 6 | 0.3% |
| 15 | REMUS PHARMACEUTICALS LIMITED | $691.0K | 1 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Meropenem exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter, June 2024 | Unknown | Unknown | Unknown | FDA issued a warning letter citing CGMP violations at the Dadra facility. |
| Sun Pharmaceutical Industries Ltd. | Warning Letter, October 2 | Unknown | Unknown | Unknown | FDA issued a warning letter for CGMP violations at the Halol facility. |
| Venus Remedies Limited | Unknown | Yes, date unknown | Yes, January 20 | Unknown | Renewed EU GMP certification from INFARMED, Portugal, in January 2025. |
| Venus Remedies Ltd | Unknown | Yes, date unknown | Yes, January 20 | Unknown | Renewed EU GMP certification from INFARMED, Portugal, in January 2025. |
| Gufic Biosciences Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
| Brooks Steriscience Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
| VHB Medi Sciences Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
| Maan Pharmaceuticals Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
| Gland Pharma Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
| Swiss Parenterals Limited | Unknown | Unknown | Unknown | Unknown | No specific regulatory data found. |
TransData Nexus reviewed the regulatory standing of 10 leading Meropenem exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 2 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Meropenem sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city's pharmaceutical sector is bolstered by a robust infrastructure, including state-of-the-art R&D centers and manufacturing facilities. This concentration of resources makes Hyderabad a critical player in the supply chain for antibiotics like Meropenem.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts several leading pharmaceutical companies, including Zydus Lifesciences and Torrent Pharmaceuticals, which are headquartered in Ahmedabad. The presence of these major firms underscores the region's significance in the production and export of finished pharmaceutical products, including Meropenem formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, provides extensive logistical advantages, facilitating the global distribution of pharmaceutical products. Sun Pharmaceutical Industries Limited, headquartered in Mumbai, is a prominent exporter of Meropenem, contributing significantly to India's pharmaceutical exports.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives and supportive government policies. This area attracts numerous pharmaceutical companies, enhancing India's capacity to produce a wide range of medications, including antibiotics like Meropenem.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 82.7% of Meropenem exports, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of potential suppliers, focusing on those located in key pharmaceutical clusters such as Hyderabad and Ahmedabad-Vadodara.
- Leverage Export Hubs: Utilize the logistical advantages of export hubs like Mumbai to streamline distribution channels and reduce lead times.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
By strategically engaging with suppliers across these key pharmaceutical clusters, companies can enhance the resilience and efficiency of their Meropenem supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Meropenem exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma partners with European firm for Meropenem delivery system
Sun Pharmaceutical Industries announced a strategic partnership with a European biotechnology firm to co-develop a novel drug delivery system for Meropenem. - IMPACT: This collaboration is expected to enhance Sun Pharma's Meropenem formulations, potentially increasing export competitiveness.
Impact: This collaboration is expected to enhance Sun Pharma's Meropenem formulations, potentially increasing export competitiveness.
Common Questions — Meropenem Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which meropenem supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 206 recorded shipments worth $89.0M. EUGIA PHARMA SPECIALITIES LIMITED (341 shipments) and VENUS REMEDIES LIMITED (801 shipments) are also established high-volume exporters.
Q How many meropenem manufacturers are there in India?
India has 401 active meropenem exporters with a combined export market of $222.9M across 3,658 shipments to 134 countries. The top 5 suppliers hold 82.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for meropenem from India?
Average FOB unit price: $3.70 per unit, ranging from $0.01 to $334.19. Average shipment value: $60.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 401 verified Indian exporters of Meropenem ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,658 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 134 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,658 Verified Shipments
401 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists